Search clinical trials for: UBRELVY

Total 13 results

AbbVie

Not yet recruiting

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Migraine
AbbVie

Recruiting

An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants (COBRA)

Migraine

Israel
AbbVie

Recruiting

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants (COURAGE II)

Migraine

United States
Chicago Headache Center & Research Institute
AbbVie

Recruiting

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies (UNION)

Headache, Migraine

United States
Messoud Ashina, MD

Recruiting

Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM)

Migraine Without Aura | Migraine With Aura

Denmark
AbbVie

Recruiting

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy (P22-392)

Migraine

United States
AbbVie

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine

United States, Puerto Rico
The Cleveland Clinic

Enrolling by invitation

Migraine Medication Effects on Urinary Symptoms

Overactive Bladder | Migraine | Migraine Disorders | Overactive Detrusor | Interstitial Cystitis | Overactive Bladder Syndrome | Bladder Pain Syndrome

United States
AbbVie

Completed

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
AbbVie

Completed

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine (TANDEM)

Episodic Migraine

United States
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine

United States, Puerto Rico
AbbVie

Completed

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Migraine

United States
Hospices Civils de Lyon

Unknown

Human Aging and in Vivo Noradrenergic System (NA_PET_MRI)

Parkinson Disease

France

3

Subscribe